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Background: A sesquiterpene endoperoxide lactone,
artemisinin (AM), has become ﬁrst-line natural antimalarial
drug highly efﬁcient in areas of multidrug resistance. The AM has
a short half-life, and is being used with long acting blood sch-
izontocidal drugs with different targets in the parasite. However,
a combination therapy was linked to adverse drug interactions,
and attributed to lower efﬁcacy of AM. A unique 1,2,4-trioxane
ring is essential for activity of the parent substrate, as all known
AM metabolites were inactive due to the endoperoxide bridge
was reduced to an epoxide. It was reafﬁrmed, both in vivo and in
human liver microsomes that AM to be principally metabolized by
CYP2B6 isozyme.
Methods & Materials: Previously, under similar circumstances
of highly potent parent drugs, and the CYP2B6 demethylasing them
into non-active products, we had developed site-directed modiﬁ-
cation of a substrate molecule by substituting its methyl groups
with isopropyl groups. The latters create steric hindranceatCYP2B6
active site thus affecting ligand binding and lowering catalysis.
Such strategy was applied in this study. While AM is biosynthe-
sized in Artemisia annual plant extracts from mevalonic acid via
dimethylallyl and isopentenyl pyrophosphates, here C-2 dimethy-
lallyl groups at pyrophosphatewere substitutedwith isopropylallyl
groups. Isopropylartemisidin (IPAM) molecule appears to retain an
intact 1,2,4-trioxane ring incorporating an endoperoxide bridge
determined by a speciﬁc LC-MS/MS assay.
Results: The IPAMwas incubatedwith human livermicrosomes
from eight different healthy donors, and concentration-time data
were assessed by a ﬁrst-order depletion model.With correlation to
themetabolic rate constants for CYP2B6probe substrates, efavirenz
and bupropion, our data revealed that IPAM was metabolized by
CYP2B6 at least 12-13 times slower than AM. Using procedure
described by Robert et al. (2005), the hydroxylated and glucuronyl-
conjugated derivatives of covalent heme adducts were determined
in urine ofPlasmodium infected mice by means of LC-MS. Namely,
the amount of covalent heme-drug adducts was identically high in
infected mice treated with 40nM AM or 40nM IPAM, compared
to mice treated with 40nM AM metabolites lacking trioxane ring
endoperoxide bridge.
Conclusion: IPAMappears to represent a newpotent antimalar-
ial drug that can target multiple stages of the parasite’s life cycle.
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Background: Through a collaboration with the European
Legionnaires’ Disease Surveillance Network (ELDSNet), which is
co-ordinated by the European Centre for Disease Prevention and
Control, travel-associated Legionnaires’ disease (TALD) cases with
likely infection in South Africa are reported to a local team for
further investigation.
Methods & Materials: All TALD cases reported by ELDSNet to
the local team between January 2010 and November 2012 were
retrospectively reviewed and analysed. All cases had stayed at or
visited an accommodation site in South Africa during the disease
incubation period (2-10 days prior to onset of illness).
Results:A total of 7 caseswas identiﬁed: twosingle cases, a clus-
ter of two cases and a complex cluster of 3 cases. The case-patients
ranged inage from48–88years (median65years) and4weremale;
country of residence included the Netherlands (n=4), United King-
dom (n=2) and Norway (n=1). All presented with pneumonia on
return from travel to South Africa, andwere conﬁrmed LD based on
urinary antigen testing. Outcome is known for 6 cases; 5 recovered
and one died. The cluster was epidemiologically linked to a single
accommodation site in Western Cape Province, while the com-
plex cluster cases reported three common accommodation sites in
two provinces (Western Cape and Eastern Cape). One of the single
cases had stayed in both residential and holiday accommodation
sites in KwaZulu-Natal, whilst the other reported staying at numer-
ous accommodation sites in Western Cape, KwaZulu-Natal and
Gauteng provinces. The cluster and complex cluster were inves-
tigated; a total of 8 accommodation sites underwent Legionella
risk assessments and water sample testing. No sites had appropri-
ate legionella monitoring and control programmes in place. High
counts of Legionella pneumophila (LP) sg1 were detected in water
samples from 2 sites, and of LP sg 2-14 at 4 sites. Common high-
risk proﬁle systems included domestic water distribution systems,
evaporative condensers and spa pools.
Conclusion: TALD cases in European tourists visiting South
Africa have occurred and will likely continue to be reported. There
is a lack of awareness amongst South African accommodation sites
with regards theneed to institute legionellamonitoring and control
programmes.
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